{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:51:15Z","timestamp":1788580275291,"version":"build-2803163510"},"reference-count":32,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2005,1,11]],"date-time":"2005-01-11T00:00:00Z","timestamp":1105401600000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2005,1]]},"abstract":"<jats:p><jats:bold>Summary:\u2002<\/jats:bold>  <jats:italic>Purpose:<\/jats:italic> To evaluate the safety and efficacy of zonisamide (ZNS) as adjunctive treatment in patients with refractory localization\u2010related epilepsy.<\/jats:p><jats:p> <jats:italic>Methods:<\/jats:italic> This was a double\u2010blind, placebo\u2010controlled study of adjunctive ZNS in 351 patients with refractory partial seizures receiving a stable regimen of one to three antiepileptic drugs (AEDs). Patients were randomized to placebo or ZNS, 100 mg, 300 mg, or 500 mg\/day (2:1:1:2) after a 12\u2010week baseline. Dose titration was undertaken over a 6\u2010week titration phase, which was followed by an 18\u2010week fixed\u2010dose assessment phase. Primary efficacy parameters were the differences between ZNS, 500 mg\/day, and placebo in the change from baseline in frequency of complex partial (CP) seizures during the fixed\u2010dose assessment phase and in the proportion of CP responders (\u226550% decrease from baseline in seizure frequency). Safety and tolerability also were assessed.<\/jats:p><jats:p> <jats:italic>Results:<\/jats:italic> Compared with placebo, the highest dose of ZNS (500 mg\/day) resulted in a significantly greater decrease in CP seizure frequency from baseline (51.2% vs. 16.3%; p &lt; 0.0001) and a significantly higher proportion of CP responders (52.3% vs. 21.3%; p &lt; 0.001). Both ZNS, 500 mg\/day, and 300 mg\/day were statistically superior to placebo in reducing the frequency of \u201call seizures\u201d and simple partial (SP) + CP seizures. For all seizures, a significant dose\u2013response relation was observed (p &lt; 0.0001).The most common adverse events were somnolence, headache, dizziness, and nausea during the titration phase and headache and pharyngitis during the fixed\u2010dose assessment phase.<\/jats:p><jats:p> <jats:italic>Conclusions:<\/jats:italic> ZNS provides dose\u2010dependent, effective, and generally well\u2010tolerated adjunctive therapy in patients with partial seizures.<\/jats:p>","DOI":"10.1111\/j.0013-9580.2005.14704.x","type":"journal-article","created":{"date-parts":[[2005,1,11]],"date-time":"2005-01-11T10:11:23Z","timestamp":1105438283000},"page":"31-41","source":"Crossref","is-referenced-by-count":52,"title":["Dose\u2010dependent Safety and Efficacy of Zonisamide: A Randomized, Double\u2010blind, Placebo\u2010controlled Study in Patients with Refractory Partial Seizures"],"prefix":"10.1111","volume":"46","author":[{"given":"Martin J.","family":"Brodie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Vespignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andras","family":"Solyom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeriy","family":"Bitenskyy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherry","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,1,11]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"867","volume-title":"Antiepileptic drugs","author":"Macdonald RL","year":"2002"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(92)90087-A"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(87)90168-5"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701941"},{"issue":"7","key":"e_1_2_6_6_2","first-page":"245","article-title":"Zonisamide depresses excitatory synaptic transmission by a presynaptic action [Abstract]","volume":"40","author":"Zhu W","year":"1999","journal-title":"Epilepsia"},{"key":"e_1_2_6_7_2","first-page":"115","article-title":"Effect of zonisamide on the release of aspartic acid and gamma\u2010aminobutyric acid from the hippocampal slices of E1 mice","volume":"20","author":"Kawai M","year":"1994","journal-title":"Neurosciences"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.1.6.1245"},{"key":"e_1_2_6_9_2","first-page":"885","volume-title":"Antiepileptic drugs","author":"Seino M","year":"2002"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(93)90011-U"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.11403.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.10.1774"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"key":"e_1_2_6_14_2","volume-title":"Nonparametric statistical methods","author":"Hollander M","year":"1973"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7066.1169"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2003.00113.x"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.2.236"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1059-1311(03)00047-5"},{"key":"e_1_2_6_19_2","first-page":"439","article-title":"Phase III clinical study of the new antiepileptic drug, AD\u2010810 (zonisamide), in patients with childhood epilepsy","volume":"42","author":"Oguni H","year":"1988","journal-title":"Jpn J Pediatr"},{"issue":"7","key":"e_1_2_6_20_2","first-page":"188","article-title":"Efficacy and tolerability of zonisamide in generalized seizures [Abstract]","volume":"42","author":"Valeriano J","year":"2001","journal-title":"Epilepsia"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01488.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-8994(00)00183-1"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(97)00069-7"},{"issue":"3","key":"e_1_2_6_24_2","first-page":"A296","article-title":"Multicenter, open\u2010label, safety and efficacy study of zonisamide in patients with progressive myoclonic epilepsy [Abstract]","volume":"58","author":"Vossler DG","year":"2002","journal-title":"Neurology"},{"issue":"7","key":"e_1_2_6_25_2","first-page":"218","article-title":"Zonisamide is effective in the treatment of myoclonus status epilepticus and myoclonus in Jakob\u2010Creutzfeldt disease [Abstract]","volume":"43","author":"Ganguly G","year":"2002","journal-title":"Epilepsia"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.43.s.9.13.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2002.20901.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1998.tb04406.x"},{"key":"e_1_2_6_29_2","first-page":"880","volume-title":"Antiepileptic drugs","author":"Mather GG","year":"2002"},{"issue":"3","key":"e_1_2_6_30_2","first-page":"A336","article-title":"Steady\u2010state drug interaction study of zonisamide and carbamazepine in patients with epilepsy [Abstract]","volume":"56","author":"Rosenfeld WE","year":"2001","journal-title":"Neurology"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004268045"},{"issue":"3","key":"e_1_2_6_32_2","first-page":"A338","article-title":"Steady\u2010state drug interaction study of zonisamide and sodium valproate in epileptic patients [Abstract]","volume":"56","author":"Smith D","year":"2001","journal-title":"Neurology"},{"issue":"3","key":"e_1_2_6_33_2","first-page":"A337","article-title":"Steady\u2010state drug interaction study of zonisamide and lamotrigine in epileptic patients [Abstract].","volume":"56","author":"Brodie M","year":"2001","journal-title":"Neurology"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.0013-9580.2005.14704.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.0013-9580.2005.14704.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T16:56:13Z","timestamp":1697388973000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.0013-9580.2005.14704.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["10.1111\/j.0013-9580.2005.14704.x"],"URL":"https:\/\/doi.org\/10.1111\/j.0013-9580.2005.14704.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}